Inhibition of Factor IX(a) Is Protective in a Rat Model of Thromboembolic Stroke

Abstract

Background and Purpose-Although used clinically to prevent stroke, there are few examples of anticoagulant investigations in the treatment of acute thromboembolic stroke in animal models. The treatment of thromboembolic stroke in experimental models has been investigated almost exclusively around the use of tissue plasminogen activator (tPA). In this study, using a rat thromboembolic stroke model, we investigated the use of an inhibitory anti-factor IX(a) monoclonal antibody (SB 249417) for the treatment of thromboembolic stroke and compared its efficacy to that of tPA. Methods-Stroke was initiated by delivering 6 clots into the internal carotid artery. After 2, 4, or 6 hours, rats received either intravenous vehicle, 10.0 mg/kg tPA, or 1.0, 2.0, or 3.0 mg/kg SB 249417. At 24 hours after stroke, infarct volumes and neurological deficits were assessed. Results-Treatment with tPA 2, 4, or 6 hours after stroke reduced infarct volumes by 35% (PϭNS), 45%, and 39%, respectively. tPA treatment did not improve neurological deficits at any time point. Treatment with SB 249417 (3.0 mg/kg) 2, 4, or 6 hours after stroke reduced infarct volumes by 44%, 50%, and 13% (PϭNS), respectively. Neurological deficits were reduced by 49%, 42%, and 13% (PϭNS), respectively. Neither mortality nor hemorrhage was affected by either treatment. Conclusions-The data indicate that the inhibition of factor IX(a) within 4 hours of thromboembolic stroke produced a more favorable outcome than tPA. When treatment was initiated 6 hours after stroke, the benefits of factor IX(a) inhibition were lost, whereas tPA continued to suppress lesion development, albeit without a corresponding improvement in functional deficits. This study suggests that cerebral ischemia and the resultant perfusion deficit are exacerbated by the activation of blood coagulation and that anticoagulants like SB 249417 may find utility in the treatment of ischemic stroke. (Stroke. 2002;33:578-585.)

Newly expressed SUR1-regulated NCCa-ATP channel mediates cerebral edema after ischemic stroke

“…We fasted Wistar rats (275−350 g) overnight, anesthetized them (ketamine, 60 mg/kg; xylazine, 7.5 mg/kg, intraperitoneally) and maintained their body temperature at approximately 37 °C. For thromboembolic stroke, we embolized seven to eight allogeneic clots through the internal carotid artery 28 . For MCE, we embolized polyvinyl alcohol (PVA) microparticles (Target Therapeutics; 150−250 μm, 600 μg in 1.5 ml heparinized saline) 29 , followed by standard permanent suture occlusion 30 .…”

Rapid Reversal of Anticoagulation Prevents Excessive Secondary Hemorrhage After Thrombolysis in a Thromboembolic Model in Rats

“…Ischemia was induced using a thromboembolic MCAO model that we previously established 12,13 based on a previous protocol from Toomey et al 14 The model has a low rate of spontaneous recanalization after MCAO, but good reperfusion after intravenous thrombolysis (Supplemental Methods; http://stroke.ahajournals.org). Two hours after MCAO, animals received rtPA intravenously (9 mg/kg; Actilyse, Boehringer Ingelheim).…”

Comparison of Ischemic Lesion Evolution in Embolic Versus Mechanical Middle Cerebral Artery Occlusion in Sprague Dawley Rats Using Diffusion and Perfusion Imaging

“…The protocol for embolus preparation used herein was modified from a protocol originally described by Toomey et al 12 Whole blood (200 L) was withdrawn from the rat 24 hours before surgery into an Eppendorf tube. The blood was promptly mixed with 1.0 National Institutes of Health (NIH) unit (10 L) of human thrombin and 4.5 L of 1 mol/L CaCl 2 for a final CaCl 2 concentration of 20 mmol/L.…”